JP2024542096A - 新規タンパク質 - Google Patents

新規タンパク質 Download PDF

Info

Publication number
JP2024542096A
JP2024542096A JP2024526578A JP2024526578A JP2024542096A JP 2024542096 A JP2024542096 A JP 2024542096A JP 2024526578 A JP2024526578 A JP 2024526578A JP 2024526578 A JP2024526578 A JP 2024526578A JP 2024542096 A JP2024542096 A JP 2024542096A
Authority
JP
Japan
Prior art keywords
protein
fusion protein
polypeptide
disease
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024526578A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542096A5 (cg-RX-API-DMAC7.html
Inventor
アシュフィールド,レベッカ
ハクスリー,フィリップ
Original Assignee
デュセンティス バイオセラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デュセンティス バイオセラピューティクス リミテッド filed Critical デュセンティス バイオセラピューティクス リミテッド
Publication of JP2024542096A publication Critical patent/JP2024542096A/ja
Publication of JP2024542096A5 publication Critical patent/JP2024542096A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024526578A 2021-11-03 2022-11-03 新規タンパク質 Pending JP2024542096A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2115803.5 2021-11-03
GBGB2115803.5A GB202115803D0 (en) 2021-11-03 2021-11-03 Novel proteins
PCT/GB2022/052764 WO2023079278A1 (en) 2021-11-03 2022-11-03 Novel proteins

Publications (2)

Publication Number Publication Date
JP2024542096A true JP2024542096A (ja) 2024-11-13
JP2024542096A5 JP2024542096A5 (cg-RX-API-DMAC7.html) 2025-10-30

Family

ID=78828504

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024526578A Pending JP2024542096A (ja) 2021-11-03 2022-11-03 新規タンパク質

Country Status (10)

Country Link
US (1) US20250026805A1 (cg-RX-API-DMAC7.html)
EP (1) EP4426719A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024542096A (cg-RX-API-DMAC7.html)
KR (1) KR20240099427A (cg-RX-API-DMAC7.html)
CN (1) CN118369334A (cg-RX-API-DMAC7.html)
AU (1) AU2022381844A1 (cg-RX-API-DMAC7.html)
CA (1) CA3236737A1 (cg-RX-API-DMAC7.html)
GB (1) GB202115803D0 (cg-RX-API-DMAC7.html)
IL (1) IL312470A (cg-RX-API-DMAC7.html)
WO (1) WO2023079278A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2626300A (en) * 2022-12-08 2024-07-24 Ducentis Biotherapeutics Ltd Mutated CD200 proteins and methods of use therof
GB202306711D0 (en) * 2023-05-05 2023-06-21 Ducentis Biotherapeutics Ltd Novel proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
DE69226871T3 (de) 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
EP1171154A2 (en) 1999-04-13 2002-01-16 Schering Corporation Uses of mammalian ox2 protein and related reagents
WO2008089022A2 (en) 2007-01-11 2008-07-24 Boehringer Ingelheim International Gmbh Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts
GB201608197D0 (en) * 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins

Also Published As

Publication number Publication date
KR20240099427A (ko) 2024-06-28
WO2023079278A1 (en) 2023-05-11
IL312470A (en) 2024-06-01
EP4426719A1 (en) 2024-09-11
CA3236737A1 (en) 2023-05-11
GB202115803D0 (en) 2021-12-15
CN118369334A (zh) 2024-07-19
US20250026805A1 (en) 2025-01-23
AU2022381844A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
AU2017264825B2 (en) CD200 mutant and its uses
JP2019531705A (ja) 操作されたポリペプチドおよびその使用
US20230192887A1 (en) Engineered anti-her2 bispecific proteins
KR20160130463A (ko) 다량체 Fc 단백질
JP7097293B2 (ja) ヒトFc受容体に結合する融合タンパク質
US20250026805A1 (en) Novel proteins
JP2022514187A (ja) IVIGの代替のための多量体ハイブリッドFc蛋白質
JP2025515191A (ja) 新規cd200融合タンパク質
JP2024546129A (ja) アルファ-l-イズロニダーゼ酵素を含む融合タンパク質及びその方法
JP2026516066A (ja) Cd200融合タンパク質
US20260116951A1 (en) Novel cd200 fusion proteins
US20240392035A1 (en) Engineered anti-her2 bispecific proteins
TW202519543A (zh) TNF-α變體融合分子
EA042608B1 (ru) Мутант cd200 и его применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251020